Percheron Therapeutics Ltd
ASX:PER

Watchlist Manager
Percheron Therapeutics Ltd Logo
Percheron Therapeutics Ltd
ASX:PER
Watchlist
Price: 0.007 AUD -6.67% Market Closed
Market Cap: 7.6m AUD

Relative Value

The Relative Value of one PER stock under the Base Case scenario is hidden AUD. Compared to the current market price of 0.007 AUD, Percheron Therapeutics Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PER Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
92
vs Industry
6
Median 3Y
104
Median 5Y
198.9
Industry
2.6
Forward
3.5
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-6.9
Industry
21.7
Forward
-0.7
vs History
vs Industry
Median 3Y
-5.1
Median 5Y
-7.3
Industry
16.6
vs History
vs Industry
Median 3Y
-5.1
Median 5Y
-7.3
Industry
22.5
vs History
92
vs Industry
54
Median 3Y
3.7
Median 5Y
4
Industry
2.3
vs History
vs Industry
90
Median 3Y
76
Median 5Y
127.2
Industry
2.9
Forward
-1.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
9
vs Industry
Median 3Y
-2.7
Median 5Y
-4.7
Industry
13.1
Forward
0.3
vs History
9
vs Industry
Median 3Y
-2.7
Median 5Y
-4.7
Industry
16.6
Forward
0.3
vs History
9
vs Industry
Median 3Y
-3.5
Median 5Y
-5.4
Industry
15.8
vs History
9
vs Industry
Median 3Y
-3.5
Median 5Y
-5.4
Industry
19.1
vs History
vs Industry
4
Median 3Y
1.8
Median 5Y
18.8
Industry
1.9

Multiples Across Competitors

PER Competitors Multiples
Percheron Therapeutics Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Percheron Therapeutics Ltd
ASX:PER
7.6m AUD 20.5 -0.5 0.2 0.2
US
Eli Lilly and Co
NYSE:LLY
942.9B USD 15.8 51.1 34.4 36.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
488B USD 5.3 19.4 15.9 20.6
CH
Roche Holding AG
SIX:ROG
252.8B CHF 4.1 26.8 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP 4.8 29.9 108.2 158.3
CH
Novartis AG
SIX:NOVN
206.2B CHF 4.6 17.8 11.3 14.6
US
Merck & Co Inc
NYSE:MRK
247.4B USD 3.9 13 9.3 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.8 9.1 10.5
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
148.6B USD 2.4 15.1 7.7 10.5
P/E Multiple
Earnings Growth PEG
AU
Percheron Therapeutics Ltd
ASX:PER
Average P/E: 23.2
Negative Multiple: -0.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
51.1
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.4
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.9
38%
0.8
CH
Novartis AG
SIX:NOVN
17.8
17%
1
US
Merck & Co Inc
NYSE:MRK
13
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
4%
3.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.1
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Percheron Therapeutics Ltd
ASX:PER
Average EV/EBITDA: 397.7
0.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.4
33%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.9
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.5
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
1%
7.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Percheron Therapeutics Ltd
ASX:PER
Average EV/EBIT: 1 707.6
0.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.9
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.6
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.3
23%
6.9
CH
Novartis AG
SIX:NOVN
14.6
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
1%
10.5
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
8%
1.3